Making Strides in HIV: Optimizing Treatment Selections and Switch Strategies

To participate in this activity, please:

Infectious disease specialists W. David Hardy, MD, AAHIVS, and David Alain Wohl, MD, explore ways to optimize therapy selections and switch strategies in the treatment of persons living with HIV infection (PLWH), including considerations for treating PLWH in a pandemic landscape. Topics include current and ongoing disparities in HIV treatment, with strategies to overcome them, an introduction to the rapid initiation of antiretroviral therapy (ART), clinical trial data on the use of 2- and 3-drug ART regimens, an exploration of the uses of long-acting injectable ART, the use of shared decision-making to engage PLWH in treatment decisions, and suggestions on how to optimize treatment outcomes for PLWH. Case studies are discussed to examine how to apply these principles to common clinical scenarios, including overcoming pill fatigue and addressing barriers in treatment-naïve individuals.

Course Credit:

2.00 AMA PRA Category 1 CreditsTM

Dates:

Opens: 2021-11-19
Closes: 2022-11-19

Target Audience:

A national audience of HIV specialists and infectious disease specialists, plus other physicians with an interest in HIV care, including primary care physicians and emergency medicine physicians.

This educational activity is supported by an independent educational grant from ViiV Healthcare.

Accreditation and Certification

The Annenberg Center for Health Sciences at Eisenhower is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The Annenberg Center for Health Sciences at Eisenhower designates this enduring activity for a maximum of 2.00 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Additional Content Planners

Eugene Cullen, MD (Peer Reviewer)
No significant relationships to disclose.

Jessica Martin, PhD (Medical Writer)
No significant relationships to disclose.

Annenberg Center for Health Sciences

Staff at the Annenberg Center for Health Sciences at Eisenhower have no relevant commercial relationships to disclose.

All of the financial relationships listed for these individuals have been mitigated.

    Presenting Faculty

  • W. David Hardy, MD, AAHIVS

    Scientific and Medical Consultant
    Adjunct Clinical Professor of Medicine
    Division of Infectious Diseases
    Keck School of Medicine of USC
    Los Angeles, California

  • David Alain Wohl, MD

    Professor of Medicine
    Division of Infectious Diseases
    Site Leader, HIV Prevention and Treatment Clinical Trials Unit at Chapel Hill
    University of North Carolina School of Medicine
    Co-Lead, UNC Viral Hemorrhagic Fever Research Working Group

Learning Objectives

  • Examine the results from recent trials on 2-drug regimens vs 3-drug regimens for HIV, including efficacy, tolerability, and safety
  • Compare and contrast the latest evidence regarding new and emerging antiretroviral therapy options for treatment-naïve and treatment-experienced patients
  • Identify those patients who would benefit from new and emerging 2-drug regimens, including long-acting injectable antiretroviral therapy
  • Develop personalized treatment strategies for patients with HIV based on patient-specific factors and in alignment with the latest evidence

Faculty Disclosures

W. David Hardy, MD, AAHIVS

Advisory Board: Gilead Sciences, Merck & Co., ViiV Healthcare

Consultant: Enochian BioSciences


David Alain Wohl, MD

Advisory Board: Gilead Sciences, Janssen Therapeutics, Merck & Co., ViiV Healthcare

Consultant: Gilead Sciences

Research Support: Gilead Sciences, Janssen Therapeutics, Merck & Co., ViiV Healthcare